TITUSVILLE, N.J., May 24 /PRNewswire/ --New data on INVEGA® SUSTENNA® (paliperidone palmitate), a long-acting injectable medicine for schizophrenia, and new data on RISPERDAL® CONSTA® (risperidone ...

A Drug's Impact on Global Symptoms and Its Effect on Positive Symptoms Are the Attributes that Most Influence Surveyed Psychiatrists' Prescribing Decisions in Schizophrenia, According to a New Report ...

The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. INVEGA SUSTENNA contains the active ingredient paliperidone palmitate.

DUBLIN, April 9, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced positive topline results from ALPINE (Aripiprazole Lauroxil and Paliperidone palmitate: INitiation Effectiveness), a ...

August 5, 2009 — The US Food and Drug Administration (FDA) has approved a long-acting, once-monthly formulation of paliperidone palmitate injection (Invega Sustenna, Janssen, a division of ...

The FINANCIAL — Three-month paliperidone palmitate, an investigational atypical antipsychotic, significantly delayed time to relapse compared to placebo in patients with schizophrenia, according to a ...

The FINANCIAL — A study published in The Journal of Clinical Psychiatry shows that long-acting INVEGA SUSTENNA (paliperidone palmitate) was effective six months longer than commonly prescribed oral ...

Tanara never thought she’d be where she is today. Leading up to and following her diagnosis with schizophrenia, she often felt alone — her symptoms led her to isolate herself from her friends, family, ...

The Food and Drug Administration has approved Invega Hafyera ™ (paliperidone palmitate), an every 6-month injection, for the treatment of schizophrenia in adults. Invega Hafyera is a long-acting ...

Using certain kinds of drugs can land you in lockup, but pharmaceutical giant Johnson & Johnson is selling a drug that it now claims can keep you out. This article was published in collaboration with ...

TITUSVILLE, N.J., Sept. 1, 2021 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved long-acting atypical ...